Essential Partners’s ProKidney PROK Stock Holding History

Essential Partners’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-528	Closed	-$313	–	2760
2025 Q2	$313	Buy	+528	New	+$411	﹤0.01%	1829

Other funds holding PROK

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brown University Providence, Rhode Island $112M AUM 3.02% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Essential Partners's PROK Position: Q3 2025 in Review

Essential Partners sold out of ProKidney (PROK) in Q3 2025, closing a stake of 528 shares — an estimated $313 sold.

Essential Partners first reported a position in PROK in Q2 2025 and held it in 1 quarter. The position peaked at $313 in Q2 2025. 56 funds tracked by Wall St. Rank hold PROK as of Q3 2025.

Essential Partners reported no remaining ProKidney position as of Q3 2025 after selling out during the quarter.
Essential Partners sold 528 ProKidney shares in Q3 2025, an estimated $313.
Essential Partners first reported a position in ProKidney in Q2 2025 and held it in 1 quarter.
Essential Partners's ProKidney position peaked at $313 in Q2 2025.
56 funds tracked by Wall St. Rank held ProKidney as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.